I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| oligodendrocyte | 8 studies | 29% ± 8% | |
| natural killer cell | 6 studies | 21% ± 5% | |
| astrocyte | 5 studies | 26% ± 8% | |
| epithelial cell | 4 studies | 27% ± 8% | |
| type I pneumocyte | 4 studies | 19% ± 2% | |
| oligodendrocyte precursor cell | 4 studies | 25% ± 7% | |
| CD8-positive, alpha-beta T cell | 4 studies | 18% ± 1% | |
| CD16-positive, CD56-dim natural killer cell, human | 3 studies | 20% ± 3% | |
| CD16-negative, CD56-bright natural killer cell, human | 3 studies | 20% ± 2% | |
| GABAergic neuron | 3 studies | 39% ± 2% | |
| glutamatergic neuron | 3 studies | 47% ± 2% | |
| dendritic cell | 3 studies | 28% ± 2% | |
| basal cell | 3 studies | 20% ± 2% | |
| plasmacytoid dendritic cell | 3 studies | 23% ± 5% | |
| effector CD8-positive, alpha-beta T cell | 3 studies | 17% ± 1% | |
| interneuron | 3 studies | 38% ± 19% |
